Literature DB >> 18812571

High-throughput screening of a 100,000-compound library for inhibitors of influenza A virus (H3N2).

William E Severson1, Michael McDowell, Subramaniam Ananthan, Dong-Hoon Chung, Lynn Rasmussen, Melinda I Sosa, E Lucile White, James Noah, Colleen B Jonsson.   

Abstract

Using a highly reproducible and robust cell-based high-throughput screening (HTS) assay, the authors screened a 100,000-compound library at 14- and 114-microM compound concentration against influenza strain A/Udorn/72 (H3N2). The "hit" rates (>50% inhibition of the viral cytopathic effect) from the 14- and 114-microM screens were 0.022% and 0.38%, respectively. The hits were evaluated for their antiviral activity, cell toxicity, and selectivity in dose-response experiments. The screen at the lower concentration yielded 3 compounds, which displayed moderate activity (SI(50) = 10-49). Intriguingly, the screen at the higher concentration revealed several additional hits. Two of these hits were highly active with an SI(50) > 50. Time of addition experiments revealed 1 compound that inhibited early and 4 other compounds that inhibited late in the virus life cycle, suggesting they affect entry and replication, respectively. The active compounds represent several different classes of molecules such as carboxanilides, 1-benzoyl-3-arylthioureas, sulfonamides, and benzothiazinones, which have not been previously identified as having antiviral/anti-influenza activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18812571      PMCID: PMC2782602          DOI: 10.1177/1087057108323123

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  21 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

2.  The syndrome of fatal influenza virus pneumonia.

Authors:  D E ROGERS; D B LOURIA; E D KILBOURNE
Journal:  Trans Assoc Am Physicians       Date:  1958

3.  Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate.

Authors:  B Eriksson; E Helgstrand; N G Johansson; A Larsson; A Misiorny; J O Norén; L Philipson; K Stenberg; G Stening; S Stridh; B Oberg
Journal:  Antimicrob Agents Chemother       Date:  1977-06       Impact factor: 5.191

Review 4.  Pandemics, avian influenza A (H5N1), and a strategy for pharmacists.

Authors:  Stephen M Ford; John D Grabenstein
Journal:  Pharmacotherapy       Date:  2006-03       Impact factor: 4.705

5.  A cell-based luminescence assay is effective for high-throughput screening of potential influenza antivirals.

Authors:  James W Noah; William Severson; Diana L Noah; Lynn Rasmussen; E Lucile White; Colleen B Jonsson
Journal:  Antiviral Res       Date:  2006-07-28       Impact factor: 5.970

Review 6.  The fight against new types of influenza virus.

Authors:  Julia Romanova
Journal:  Biotechnol J       Date:  2006-12       Impact factor: 4.677

7.  Influenza-associated hospitalizations in the United States.

Authors:  William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Carolyn B Bridges; Nancy J Cox; Keiji Fukuda
Journal:  JAMA       Date:  2004-09-15       Impact factor: 56.272

8.  Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007.

Authors:  Anthony E Fiore; David K Shay; Penina Haber; John K Iskander; Timothy M Uyeki; Gina Mootrey; Joseph S Bresee; Nancy J Cox
Journal:  MMWR Recomm Rep       Date:  2007-07-13

Review 9.  Antiviral agents active against influenza A viruses.

Authors:  Erik De Clercq
Journal:  Nat Rev Drug Discov       Date:  2006-12       Impact factor: 84.694

Review 10.  Vaccines for pandemic influenza.

Authors:  Catherine J Luke; Kanta Subbarao
Journal:  Emerg Infect Dis       Date:  2006-01       Impact factor: 6.883

View more
  19 in total

1.  Assays for the identification of novel antivirals against bluetongue virus.

Authors:  Linlin Gu; Stewart W Schneller; Qianjun Li
Journal:  J Vis Exp       Date:  2013-10-11       Impact factor: 1.355

2.  Identification of small-molecule inhibitors of ricin and shiga toxin using a cell-based high-throughput screen.

Authors:  Paul G Wahome; Yan Bai; Lori M Neal; Jon D Robertus; Nicholas J Mantis
Journal:  Toxicon       Date:  2010-03-27       Impact factor: 3.033

3.  Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus.

Authors:  Jizhou Wang; Chunlong Ma; Jun Wang; Hyunil Jo; Belgin Canturk; Giacomo Fiorin; Lawrence H Pinto; Robert A Lamb; Michael L Klein; William F DeGrado
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

Review 4.  Adapting high-throughput screening methods and assays for biocontainment laboratories.

Authors:  Lynn Rasmussen; Bersabeh Tigabu; E Lucile White; Robert Bostwick; Nichole Tower; Alexander Bukreyev; Barry Rockx; James W LeDuc; James W Noah
Journal:  Assay Drug Dev Technol       Date:  2015 Jan-Feb       Impact factor: 1.738

5.  Human microRNAs profiling in response to influenza A viruses (subtypes pH1N1, H3N2, and H5N1).

Authors:  Jarika Makkoch; Witthaya Poomipak; Suthat Saengchoowong; Kritsada Khongnomnan; Kesmanee Praianantathavorn; Thananya Jinato; Yong Poovorawan; Sunchai Payungporn
Journal:  Exp Biol Med (Maywood)       Date:  2015-10-29

6.  A BSL-4 high-throughput screen identifies sulfonamide inhibitors of Nipah virus.

Authors:  Bersabeh Tigabu; Lynn Rasmussen; E Lucile White; Nichole Tower; Mohammad Saeed; Alexander Bukreyev; Barry Rockx; James W LeDuc; James W Noah
Journal:  Assay Drug Dev Technol       Date:  2014-04       Impact factor: 1.738

7.  A high-throughput screening strategy to overcome virus instability.

Authors:  Lynn Rasmussen; Clinton Maddox; Blake P Moore; William Severson; E Lucile White
Journal:  Assay Drug Dev Technol       Date:  2010-11-04       Impact factor: 1.738

8.  The development, optimization and validation of an assay for high throughput antiviral drug screening against Dengue virus.

Authors:  Pulin Che; Lihua Wang; Qianjun Li
Journal:  Int J Clin Exp Med       Date:  2009-12-08

9.  (S)-N-(2,5-Dimethylphenyl)-1-(quinoline-8-ylsulfonyl)pyrrolidine-2-carboxamide as a small molecule inhibitor probe for the study of respiratory syncytial virus infection.

Authors:  Blake P Moore; Dong Hoon Chung; Daljit S Matharu; Jennifer E Golden; Clinton Maddox; Lynn Rasmussen; James W Noah; Melinda I Sosa; Subramaniam Ananthan; Nichole A Tower; E Lucile White; Fuli Jia; Thomas E Prisinzano; Jeffrey Aubé; Colleen B Jonsson; William E Severson
Journal:  J Med Chem       Date:  2012-10-16       Impact factor: 7.446

10.  Assay development and high-throughput antiviral drug screening against Bluetongue virus.

Authors:  Qianjun Li; Clinton Maddox; Lynn Rasmussen; Judith V Hobrath; Lucile E White
Journal:  Antiviral Res       Date:  2009-06-24       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.